Enhanced Therapeutic Efficacy of Immunostimulatory CpG-ODN by Silencing SOCS-1 with Polysaccharide/miR-155 Complexes

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Adjuvants and antigens are crucial for antigen-specific immune responses.
• CpG-oligodeoxynucleotides (CpG-ODN) activate toll-like receptor 9 (TLR9) and act as adjuvants.
• Suppressor of cytokine signaling-1 (SOCS-1) negatively regulates TLR9 signaling, dampening adjuvant effects.

Purpose of the Study:

• To develop a more potent immune response strategy by combining microRNA-155 (miR-155) with CpG-ODN.
• To overcome SOCS-1-mediated suppression of TLR9 signaling using miR-155.
• To evaluate the therapeutic potential of SPG/miR-155 and SPG/CpG complexes in cancer treatment.

Main Methods:

• Schizophyllan (SPG) was used to form complexes with miR-155 (SPG/miR-155) and CpG-ODN (SPG/CpG).
• These complexes were delivered to antigen-presenting cells (APCs) in draining lymph nodes.
• The efficacy of SPG/miR-155 and SPG/CpG combination therapy was assessed in a mouse tumor model.

Main Results:

• Efficient delivery of miR-155 to APCs by SPG complexes significantly enhanced cellular immune responses compared to SPG/CpG alone.
• Mice treated with the combination of SPG/miR-155 and SPG/CpG exhibited a prolonged delay in tumor growth.
• Combination therapy led to improved survival rates in tumor-inoculated mice.

Conclusions:

• Combining miR-155 and CpG-ODN, complexed with SPG, offers a potent strategy for cancer immunotherapy.
• This approach effectively enhances anti-tumor cellular immune responses.
• The findings suggest a promising therapeutic avenue for cancer treatment.